Free Trial
NYSE:MTNB

Matinas Biopharma 8/14/2024 Earnings Report

Matinas Biopharma logo
$0.71 +0.07 (+11.39%)
Closing price 03:59 PM Eastern
Extended Trading
$0.70 -0.01 (-0.85%)
As of 04:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Matinas Biopharma EPS Results

Actual EPS
-$0.02
Consensus EPS
-$0.02
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Matinas Biopharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Matinas Biopharma Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Matinas Biopharma Earnings Headlines

Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.
See More Matinas Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Matinas Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Matinas Biopharma and other key companies, straight to your email.

About Matinas Biopharma

Matinas Biopharma (NYSE:MTNB) is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

View Matinas Biopharma Profile

More Earnings Resources from MarketBeat